EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Maike Stein iD, Maximilian Mönch, Meret Herdick, Frauke Stascheit iD, Sarah Hoffmann iD, Hannah Preßler, Philipp Mergenthaler iD, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel und 2 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70293 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Maike Stein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology With Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Un…. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Argenx, Hormosan, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients. This study evaluated whether frequently assessed clinical outcomes via MyaLink can capture symptom variability between clinical visits.

Methods

In this randomized, controlled, 12‐week study, 45 MG patients received either standard care (control, N = 15) or standard care with additional telemedical treatment (intervention, N = 30) including assessment of patient‐reported outcome measures, sensor‐based data, and patient‐physician messaging via a mobile application. Physicians performed telemedical check‐ups (TCUs) via a web‐based platform, adjusting treatment as needed.

Results

In the intervention group, variability in clinical scores and sensor‐derived data was observed, particularly among those who experienced MG‐related hospitalizations or exacerbations (H&E subgroup). This subgroup showed larger MG‐ADL score fluctuations (mean range: 5.8 vs. 2.6 points), sent more messages, had more steroid dose adjustments (40% vs. 0%), and more frequent TCU interventions (93.3% vs. 60%) than the Non‐H&E subgroup.

Interpretation

Telemedical platforms in MG might detect early signs of worsening. High‐risk patients (H&E subgroup) require increased medical support, which can be effectively addressed through MyaLink. Trial Registration The study was registered under the German clinical trial registry (DRKS00029907)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisHumansFemaleMaleMiddle AgedRemote Patient MonitoringAdultAgedTelemedicinePatient Reported Outcome Measures

Stichwörter der Autor:innen

disease progressionmonitoringmyasthenia gravisremote consultationtelemedicine

Autor:innen und Institutionen

  • Department of Neurology With Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Neuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neurology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA.
  • Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Maike Stein, Frauke Stascheit, Sarah Hoffmann, Philipp Mergenthaler, Lea Gerischer, Sophie Lehnerer

Förderung

  • Argenx
  • Hormosan
  • Deutsche Forschungsgemeinschaft
  • UCB Pharma Germany

Zitieren

APA

Stein, M., Mönch, M., Herdick, M., Stascheit, F., Hoffmann, S., Preßler, H., Mergenthaler, P., Dusemund, C., Doksani, P., Sun, H., Narayanaswami, P., Meisel, A., Gerischer, L., & Lehnerer, S. (2026). Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70293

Vancouver

Stein M, Mönch M, Herdick M, Stascheit F, Hoffmann S, Preßler H, et al. Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70293

BibTeX
@article{Stein2026,
  author = {Stein, Maike and Mönch, Maximilian and Herdick, Meret and Stascheit, Frauke and Hoffmann, Sarah and Preßler, Hannah and Mergenthaler, Philipp and Dusemund, Carla and Doksani, Paolo and Sun, Haoqi and Narayanaswami, Pushpa and Meisel, Andreas and Gerischer, Lea and Lehnerer, Sophie},
  title = {Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70293}
}
Kostenlos starten →